Next quarter’s earnings estimate for MEIP is -$2.80 with a range of -$3.56 to -$1.89. The previous quarter’s EPS was -$2.32. MEIP beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.63% of the time in the same period. In the last calendar year MEIP has Outperformed its overall industry.

MEIP Sales Forecast

Next quarter’s sales forecast for MEIP is $621.00K with a range of $0.00 to $1.11M. The previous quarter’s sales results were $5.89M. MEIP beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 44.67% of the time in the same period. In the last calendar year MEIP has Outperformed its overall industry.

MEIP Analyst Recommendation Trends

MEIP has not received any ratings in the last 3 months.

Detailed List of Analyst Forecasts

Stephen Willey

Stifel Nicolaus

$10.00

Hold

36.24%

Upside

Reiterated

2023-06-03

Stifel Nicolaus Sticks to Its Hold Rating for MEI Pharma (MEIP)

Leah R. Cann

Brookline Capital Markets

$80.00

Buy

989.92%

Upside

Reiterated

2023-05-23

MEI Pharma phase 1b voruciclib data 'encouraging,' says BrooklineMEI Pharma phase 1b voruciclib data 'encouraging,' says Brookline

Andrew Fein

H.C. Wainwright

$40.00

Buy

444.96%

Upside

Reiterated

2023-02-13

MEI Pharma price target lowered to $2 from $5 at H.C. WainwrightMEI Pharma price target lowered to $2 from $5 at H.C. Wainwright

Chris Howerton

Jefferies

$2.00

Sell

-72.75%

Downside

Downgraded

2023-02-08

Jefferies Downgrades MEI Pharma to Underperform, Lowers Price Target to $0.1

Robyn Karnauskas

Truist Financial

―

Hold

―

Downgraded

2022-12-06

Truist Securities Downgrades MEI Pharma to Hold

Unknown Analyst

Not Ranked

LifeSci Capital

―

Hold

―

Reiterated

2022-11-15

Last night MEI Pharma reported its ﬁscal Q1 2023 (calendar Q3 2022) results. Remember that MEI got entangled in a recent campaign by the FDA to modify the accelerated approval pathway. Despite generang what we think are best-in-class clinical eﬃcacy and safety data in a single-arm study with zandelisib (PI3Kd inhibitor) in r/r follicular lymphoma (FL), the FDA has essenally removed the accelerated approval pathway for drugs in the PI3Kd class. MEI Pharma is currently enrolling a randomized conﬁrmatory trial (COASTAL, ﬁrst paent dosed in 2nd line FL paents. We previously noted two ways in which the MEI Pharma story could have posive upside prior to the readout of COASTAL, one of which was predicated on the umbralisib of this year, although the outcome of that meeng was not in the favor of the PI3Kd class.

Best Analysts Covering MEI Pharma

Which Analyst Should I Follow If I Want to Buy MEIP and Sell After:

1 Month

Leah R. CannBrookline Capital Markets

Success Rate

11/33 ratings generated profit

Average Return

+2.16%

reiterated a buy rating 4 months ago

Copying Leah R. Cann's trades and holding each position for 1 Month would result in 33.33% of your transactions generating a profit, with an average return of +2.16% per trade.

dummydummy

Success Rate

0/0 ratings generated profit

Average Return

0.00%

a rating ―

Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.

Premium Content

Find out which analyst has the highest Average Return & Success Rate

Go Premium

3 Months

Leah R. CannBrookline Capital Markets

Success Rate

14/33 ratings generated profit

Average Return

-1.63%

reiterated a buy rating 4 months ago

Copying Leah R. Cann's trades and holding each position for 3 Months would result in 42.42% of your transactions generating a profit, with an average return of -1.63% per trade.

dummydummy

Success Rate

0/0 ratings generated profit

Average Return

0.00%

a rating ―

Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.

Premium Content

Find out which analyst has the highest Average Return & Success Rate

Go Premium

1 Year

Leah R. CannBrookline Capital Markets

Success Rate

11/33 ratings generated profit

Average Return

-14.50%

reiterated a buy rating 4 months ago

Copying Leah R. Cann's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -14.50% per trade.

2 Years

Leah R. CannBrookline Capital Markets

Success Rate

6/32 ratings generated profit

Average Return

-34.26%

reiterated a buy rating 4 months ago

Copying Leah R. Cann's trades and holding each position for 2 Years would result in 18.75% of your transactions generating a profit, with an average return of -34.26% per trade.

dummydummy

Success Rate

0/0 ratings generated profit

Average Return

0.00%

a rating ―

Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.

Premium Content

Find out which analyst has the highest Average Return & Success Rate

Go Premium

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxxxxxxxxxxxxxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

MEIP Stock Forecast FAQ

What is MEIP’s average 12-month price target, according to analysts?

Currently, no data Available

What is MEIP’s upside potential, based on the analysts’ average price target?

Currently there's no upside potential for MEIP, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is MEIP a Buy, Sell or Hold?

Currently, no data Available

What is MEI Pharma’s price target?

Currently, no data Available

What do analysts say about MEI Pharma?

Not enough analysts have published a price target to provide an average price target.

How can I buy shares of MEIP?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

MEI Pharma (MEIP) Stock Forecast & Price Target

MEIP Analyst Ratings

MEIP Stock 12 Months Forecast

MEIP Financial Forecast

MEIP Earnings Forecast

MEIP Sales Forecast

MEIP Analyst Recommendation Trends

Detailed List of Analyst Forecasts​

Best Analysts Covering MEI Pharma

MEIP Stock Forecast FAQ

Get More with TipRanks Premium

Detailed List of Analyst Forecasts